MedTrace Logo

French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings

NCT01700582 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 17664

Last updated 2023-07-21

No results posted yet for this study

Summary

The French National Cancer Institute (INCa) support a 28 hospital platforms network for molecular testing of cancer patients. These platforms routinely assess a panel of biomarkers in order to speed up access of French cancer patients to targeted therapies (commercially available or through clinical trials).

The objective of the BIOMARKERS-France study is to describe the epidemiological, clinical and molecular characteristics of these patients and their tumors and to assess the impact of these analyzes on their treatment (ie bio-guided therapy) as well as outcomes (response rate, progression free and overall survival).

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • ALK Gene Mutation
  • KRAS Gene Mutation
  • BRAF Gene Mutation

Sponsors & Collaborators

  • Intergroupe Francophone de Cancerologie Thoracique

    lead OTHER

Principal Investigators

  • Fabrice Barlesi, PhD, MD · IFCT, Aix Marseille Université / Assistance Publique Hôpitaux de Marseille

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01700582 on ClinicalTrials.gov